Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Patients using Enerzair® and Atectura® Breezhaler® to manage their uncontrolled asthma in Japan will have the option to enroll in Propeller’s digital health platform to help manage their condition.
Product Name : Enerzair Breezhaler
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 26, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration